PCM
TVTX icon

Penn Capital Management’s Travere Therapeutics TVTX Stock Holding History

Penn Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$377K Buy
12,676
+809
+7% +$24.2K 0.03% 165
2025
Q4 		$453K Sell
11,867
-15,137
-56% -$492K 0.04% 152
2025
Q3 		$645K Buy
27,004
+7,680
+40% +$144K 0.05% 132
2025
Q2 		$286K Sell
19,324
-1,770
-8% -$29.3K 0.02% 147
2025
Q1 		$378K Buy
+21,094
New +$428K 0.04% 137

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Penn Capital Management's TVTX Position: Q1 2026 in Review

Penn Capital Management increased its Travere Therapeutics (TVTX) stake by 6.8% in Q1 2026, buying an estimated $24.2K and bringing the position to 12,676 shares worth $377K. The position accounts for 0.03% of the portfolio, ranked #165.

Penn Capital Management first reported a position in TVTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $645K in Q3 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Penn Capital Management held 12,676 shares of Travere Therapeutics worth $377K as of Q1 2026.
  • Penn Capital Management bought 809 Travere Therapeutics shares in Q1 2026, an estimated $24.2K.
  • Travere Therapeutics made up 0.03% of Penn Capital Management's portfolio in Q1 2026, its #165 holding.
  • Penn Capital Management first reported a position in Travere Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Penn Capital Management's Travere Therapeutics position peaked at $645K in Q3 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Penn Capital Management's 13F filing for Q1 2026, filed 7 May 2026.